INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1%
Wed, 14 Aug

INDOCO REMEDIES has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:

INDOCO REMEDIES Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-18*
3
Mar-19*
3
Jun-19*
QoQ ChangeYoY Change
Net SalesRs m2,1752,5202,5270.3%16.2%
Other incomeRs m3496-87.0%106.5%
TurnoverRs m2,1782,5702,533-1.4%16.3%
ExpensesRs m2,0602,2352,2992.9%11.6%
Gross profitRs m116286228-20.3%96.6%
DepreciationRs m167195170-12.7%1.6%
InterestRs m72466132.2%-14.8%
Profit before taxRs m-120943-97.0%
TaxRs m0-22-190.0%
Profit after taxRs m-12011622-81.3%
Gross profit margin%5.311.39.0
Effective tax rate%0.0-23.7-678.6
Net profit margin%-5.54.50.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 16.2% on a year-on-year (YoY) basis. The expenses were up by 11.6% YoY during the same period.
  • The company's operating profit increased by 96.6% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 9.0% in 1QFY20 as against 5.3% in 1QFY19.
  • Depreciation charges increased by 1.6% and finance costs declined by 14.8% YoY, respectively.
  • Other income increased by 106.5% YoY during the quarter.
  • Net profit for the quarter increased by 118.1% YoY. Net profit margins during the quarter increased from -5.5% in 1QFY19 to 0.9% in 1QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 0.3% on a quarter-on-quarter (QoQ) basis. The expenses were up by 2.9% QoQ during the same period.
  • The company's operating profit declined by 20.3% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 9.0% in 1QFY20 as against 11.3% in 4QFY19.
  • Net profit for the quarter declined by 81.3% QoQ, while net profit margins declined from 4.5% in 4QFY19 to 0.9% in 1QFY20.

To see how INDOCO REMEDIES has performed over the last eight quarters,please visit here.

INDOCO REMEDIES Share Price Performance

Over the last one year,INDOCO REMEDIES share price has moved down from Rs 196.0 to Rs 154.6, registering a Loss of Rs 41.4 or around 21.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,484.3 (down 0.7%). Over the last one year it has moved down from 14,687.0 to 12,484.3, a gain of 2,203 points (down 15.0%).

Overall, the S&P BSE SENSEX is down 0.6% over the year.

Current Valuations

At the current price of Rs 154.6, the price to earnings (P/E) ratio of INDOCO REMEDIES stands at 125.4 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.1 times.

Equitymaster requests your view! Post a comment on "INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1%". Click here!

  

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Oct 23, 2019 10:13 AM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - IIFL FINANCE COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS